Skin Autofluorescence as a Predictor of Bone Fragility in Type 1 Diabetes: A Critical Appraisal of the Evidence

In their cross-sectional study, Brandt et al. propose skin autofluorescence (SAF) as a potential predictor of impaired bone quality in type one diabetes, a hypothesis of significant clinical interest. This letter provides a critical appraisal of this claim. While the biological rationale linking advanced glycation endproducts to bone matrix properties is sound, we argue that the study's cross-sectional design fundamentally limits its ability to establish predictive utility, as it can only demonstrate association, not causation or forecasting of future events. Furthermore, the modest improvement in the area under the curve lacks a demonstrated meaningful clinical impact, such as net reclassification improvement. The assumption that dermal SAF accurately reflects the skeletal advanced glycation endproduct pool remains unvalidated and may be confounded by systemic disease severity. We conclude that while the findings are hypothesis-generating, prospective longitudinal studies and direct tissue validation are imperative before SAF can be considered a validated clinical predictor.